^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

PGR (Progesterone receptor)

i
Other names: PGR, Progesterone receptor, Nuclear receptor subfamily 3 group C member 3, NR3C3
20h
Src-dependent modulation of IFNγ-induced PD-L1 expression in human breast cancer cell lines. (PubMed, J Pharmacol Sci)
These findings indicate that Src plays a crucial role in IFNγ-mediated PD-L1 expression and immune evasion in TNBC cell lines. Src inhibition may represent a promising combinatorial strategy to enhance antitumor immunity in TNBC cell lines.
Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma)
|
PD-L1 expression • HER-2 expression
1d
Effects of hysteroscopic cold knife technique on the treatment of endometrial polyps and its protective effect on the endometrium. (PubMed, Am J Transl Res)
Hysteroscopic cold knife technology is an effective and minimally invasive treatment for endometrial polyps, with rapid postoperative recovery and protective effects on the endometrium.
Journal
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CRP (C-reactive protein)
2d
Prospective Phase II Multicenter Trial of Ablation after Breast Lumpectomy Added To Extend (ABLATE) Intraoperative Margins for the Sole Local Treatment of Breast Cancer. (PubMed, Ann Surg Oncol)
A majority of the subjects avoided whole breast XRT and mastectomy. Results indicate that eRFA, in lieu of XRT, is safe and effective, resulting in ~fivefold lower pain. By completing therapy in the operating room, eRFA can potentially enhance patient access and compliance, alleviate financial stress, and deliver superior cosmetic and quality-of-life outcomes.
P2 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
|
HER-2 negative
3d
MACS: Diet Modification in pAtients With Luminal Early Breast Cancer Candidate for Primary Surgery (clinicaltrials.gov)
P=N/A, N=75, Recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Trial completion date: Apr 2026 --> Dec 2026 | Trial primary completion date: Apr 2026 --> Dec 2026
Trial completion date • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • PGR positive
3d
Solid Papillary Carcinoma of the Breast-A Case Treated with Total Mastectomy Following Preoperative Diagnosis of Mass-Forming Ductal Carcinoma (PubMed, Gan To Kagaku Ryoho)
Postoperatively, the patient was started on tamoxifen, and she remains recurrence-free to date. This case underscoring the importance of careful pre-treatment assessment of malignancy.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • SYP (Synaptophysin)
|
ER positive • HER-2 amplification • PGR positive
|
tamoxifen
3d
Pleomorphic Invasive Lobular Carcinoma Developed after Surgery for Simultaneous Ipsilateral Multiple Cancers (PubMed, Gan To Kagaku Ryoho)
The results were ER negative, PgR positive, HER2 negative, and Ki-67 25%. As the prognosis and treatment of invasive lobular carcinoma was unclear, caution was required.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative • PGR positive
3d
A Case of Early Breast Cancer Which Transient CEA Elevation after Treatment with Immune Checkpoint Inhibitors (PubMed, Gan To Kagaku Ryoho)
The efficacy of perioperative treatment with pembrolizumab for early-stage triple-negative breast cancer(TNBC)at high risk of recurrence was demonstrated in the KEYNOTE-522 trial, and it's indication was expanded in Japan as of September 2022...As follow-up continued, CEA levels began to decline and the thymic enlargement showed a tendency to regress. These findings suggest a potential association between immune checkpoint inhibitor and thymic enlargement, as well as a possible link to the observed CEA elevation.
Journal • Checkpoint inhibition
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 negative • ER negative
|
Keytruda (pembrolizumab)
3d
A Case of T4b Breast Cancer That Developed 17 Years after Radiofrequency Ablation (PubMed, Gan To Kagaku Ryoho)
After that, trastuzumab+pertuzumab was administered 17 times. Currently, the patient is being followed up with fulvestrant. Two years after surgery, there has been no obvious metastasis or recurrence.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
HER-2 positive • ER positive • PGR positive
|
Herceptin (trastuzumab) • Perjeta (pertuzumab) • fulvestrant
3d
A Case of Tubular Carcinoma of the Breast (PubMed, Gan To Kagaku Ryoho)
Tubular carcinoma is pathologically characterized by a high amount of fibrous stroma surrounding the lumen, and ultrasound findings often show a hypoechoic mass with unclear boundaries and attenuation of posterior echoes. In this case, ultrasound examination was also useful in estimating the histological type.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive
4d
Unravelling the structural impact of progesterone receptor mutations in myoma and progesterone intolerance through computational modeling. (PubMed, Comput Biol Med)
These findings were further validated through the use of allostery predictions. Our results reveal distinct mechanisms by which PR mutations modulate receptor function, laying the framework for future mechanistic studies and therapeutic development for PR-associated reproductive disorders.
Journal
|
PGR (Progesterone receptor)
4d
Can Large Language Models Reduce the Cost of Extracting Data from Electronic Health Records for Research? (PubMed, medRxiv)
LLMs exhibit lower hands-on development costs compared to standard NLP techniques, but require significant and potentially costly computation resources. LLMs may potentially allow the economically competitive application of NLP to smaller projects if computation costs can be managed.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
4d
Ovarian mesonephric-like adenocarcinoma mimicking serous carcinoma: A case report integrating cytologic, frozen, histological, immunohistochemistry, and molecular analyses. (PubMed, Int J Surg Case Rep)
This case underscores the diagnostic challenges of MLA, particularly its ability to masquerade as low-grade or high-grade serous carcinoma on morphology, including cytology, frozen, and permanent sections. We compare the cytologic, histologic, immunophenotypic, and molecular features of MLA and serous carcinoma, highlighting the importance of thorough evaluation to avoid the pitfall of morphology-only diagnosis.
Journal • Tumor mutational burden
|
KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PGR (Progesterone receptor) • TMB (Tumor Mutational Burden) • NKX2-1 (NK2 Homeobox 1) • GATA3 (GATA binding protein 3) • PAX8 (Paired box 8)
|
KRAS mutation • TP53 wild-type • TMB-L • KRAS G12